Trials / Recruiting
RecruitingNCT05764538
DAOIB for the Treatment of Brain Fog
DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 -An Open Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chang Gung Memorial Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DAOIB | The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2023-03-10
- Last updated
- 2026-03-19
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT05764538. Inclusion in this directory is not an endorsement.